TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled ...
The FDA approved pegloticase (Krystexxa) injection coadministered with methotrexate, Horizon Therapeutics announced Friday. Pegloticase is currently the only FDA-approved medication used to reduce ...
Credit: Getty Images. ADX-2191 is a preservative-free, intravitreal formulation of methotrexate designed to be vitreous-compatible. The New Drug Application (NDA) for ADX-2191 (methotrexate injection) ...
DUBLIN--(BUSINESS WIRE)--Horizon Pharma plc (Nasdaq: HZNP) enrolled the first patient in a clinical trial evaluating the use of KRYSTEXXA® (pegloticase injection) with methotrexate to sustain lower ...
NEW YORK CITY -- Postoperative intravitreal methotrexate for retinal detachment led to a significant reduction in reoperation and improved visual acuity, a retrospective chart review showed. The ...
LONG BEACH, Calif. -- Methotrexate, during and after surgery for primary retinal detachment, has produced "amazing" early results in preventing proliferative vitreoretinopathy (PVR), according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback